Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 30;12(12):3574. doi: 10.3390/cancers12123574

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Prediction of Pembrolizumab subjects. Discrimination between the metabolomic profiles of baseline serum samples (T0) from nivolumab- and pembrolizumab- treated subjects. Score plots of (A) PCA analysis; (B) O-PLS analysis. In each score plot, each dot represents a different serum sample. Purple dots: nivolumab; green dots: pembrolizumab. (C) Prediction of pembrolizumab-treated subjects. O-PLS analysis of T0 serum samples. Score plot, PC1 vs. PC2, and corresponding confusion matrix. Red dots: nivolumab responder subjects; blues dots: nivolumab non-responder subjects. Red crosses: pembrolizumab subjects predicted as non-responders; blue crosses: pembrolizumab subjects predicted as responders.